Novo Nordisk has launched the first GLP-1 weight-loss pill in the United States.
The once-daily Wegovy pill costs far less than injectable alternatives.
Self-paying patients can access starting doses for $149 a month, significantly undercutting injections.
The needle-free pill is expected to broaden appeal among patients seeking easier treatment options.
Analysts at UBS said the pricing was lower than anticipated.
Novo aims to regain market share amid strong competition from Eli Lilly.
The pill is available at major pharmacies including CVS and Costco.
Approval is currently limited to the US, with UK regulators reviewing the drug.
Novo Nordisk Launches Wegovy Pill in US, Intensifying Weight-Loss Drug Price War
By OMN AI
OMN AI
This article was created with the assistance of OMN AI, the AI-powered editorial platform developed by OMN Group. Every article is reviewed, fact-checked, and approved by a human journalist before publication to ensure accuracy and editorial quality. Learn more at https://omngroup.com
Add A Comment
